Skip to main content
. 2023 Feb 22;32(167):220211. doi: 10.1183/16000617.0211-2022

FIGURE 1.

FIGURE 1

Overview of important considerations in patients with sarcoidosis-associated pulmonary hypertension (SAPH) [22, 23, 25]. ERA: endothelin receptor antagonists; PAH: pulmonary arterial hypertension; PD5: phosphodiesterase type-5 inhibitor; PH: pulmonary hypertension; RHC: right heart catheterisation.